OraSure Technologies, Inc. (NASDAQ:OSUR) Director John P. Kenny Purchases 47,659 Shares

OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report) Director John P. Kenny acquired 47,659 shares of OraSure Technologies stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average cost of $3.17 per share, with a total value of $151,079.03. Following the completion of the purchase, the director now owns 70,915 shares in the company, valued at $224,800.55. The trade was a 204.93 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

OraSure Technologies Trading Up 2.6 %

OraSure Technologies stock traded up $0.09 during trading on Monday, hitting $3.57. The company had a trading volume of 1,153,365 shares, compared to its average volume of 959,187. The stock has a market cap of $266.30 million, a price-to-earnings ratio of 23.80 and a beta of 0.05. OraSure Technologies, Inc. has a 1-year low of $2.68 and a 1-year high of $7.43. The company's 50 day simple moving average is $3.78 and its 200-day simple moving average is $4.00.

Institutional Investors Weigh In On OraSure Technologies

A number of large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in OraSure Technologies by 202.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 5,234 shares during the last quarter. Causeway Capital Management LLC acquired a new stake in shares of OraSure Technologies during the fourth quarter worth $36,000. Raymond James Financial Inc. purchased a new position in OraSure Technologies in the 4th quarter valued at $37,000. Boothbay Fund Management LLC acquired a new position in OraSure Technologies in the 4th quarter valued at $42,000. Finally, Gotham Asset Management LLC purchased a new position in OraSure Technologies during the 4th quarter worth $43,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered OraSure Technologies from a "buy" rating to a "hold" rating in a research note on Saturday, February 22nd.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.